» Articles » PMID: 30521480

GLUT3 Expression in Cystic Change Induced by Hypoxia in Pituitary Adenomas

Overview
Journal Endocr Connect
Specialty Endocrinology
Date 2018 Dec 7
PMID 30521480
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor cells require large amounts of energy to sustain growth. Through the mediated transport of glucose transporters, the uptake and utilization of glucose by tumor cells are significantly enhanced in the hypoxic microenvironment. Pituitary adenomas are benign tumors with high-energy metabolisms. We aimed to investigate the role of expression of glucose transporter 3 (GLUT3) and glucose transporter 1 (GLUT1) in pituitary adenomas, including effects on size, cystic change and hormone type. Pituitary adenomas from 203 patients were collected from January 2013 to April 2017, and immunohistochemical analysis was used to detect the expression of GLUT3 and GLUT1 in tumor specimens. GLUT3-positive expression in the cystic change group was higher than that in the non-cystic change group (P = 0.018). Proportions of GLUT3-positive staining of microadenomas, macroadenomas, and giant adenomas were 22.7 (5/22), 50.4 (66/131) and 54.0% (27/50), respectively (P = 0.022). In cases of prolactin adenoma, GLUT3-positive staining was predominant in cell membranes (P = 0.000006), while in cases of follicle-stimulating hormone or luteotropic hormone adenoma, we found mainly paranuclear dot-like GLUT3 staining (P = 0.025). In other hormonal adenomas, GLUT3 was only partially expressed, and the intensity of cell membrane or paranuclear punctate staining was weak. In contrast to GLUT3, GLUT1 expression was not associated with pituitary adenomas. Thus, our results indicate that the expression of GLUT3 in pituitary adenomas is closely related to cystic change and hormonal type. This study is the first to report a unique paranuclear dot-like GLUT3 staining pattern in pituitary adenomas.

Citing Articles

Relationship between MRI features and HIF-1α, GLUT1 and Ki-67 expression in pituitary adenoma with cystic degeneration.

Zhang F, Pan Z, Wu J, Huang Y BMC Med Imaging. 2025; 25(1):76.

PMID: 40050749 PMC: 11887064. DOI: 10.1186/s12880-025-01574-8.


Predictive value of cyst/tumor volume ratio of pituitary adenoma for tumor cell proliferation.

Wu J, Zhang F, Huang Y, Wei L, Mei T, Wang S BMC Med Imaging. 2024; 24(1):69.

PMID: 38515047 PMC: 10958862. DOI: 10.1186/s12880-024-01246-z.

References
1.
Han X, Sun S, Zhao M, Cheng X, Chen G, Lin S . Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis. PLoS One. 2014; 9(11):e112470. PMC: 4226555. DOI: 10.1371/journal.pone.0112470. View

2.
Kristof R, Aliashkevich A, Hans V, Haun D, Meyer B, Thees C . The regional oxygen saturation of pituitary adenomas is lower than that of the pituitary gland: microspectrophotometric study with potential clinical implications. Neurosurgery. 2003; 53(4):880-5. DOI: 10.1227/01.neu.0000083604.09901.f6. View

3.
Semple P, Jane J, Lopes M, Laws E . Pituitary apoplexy: correlation between magnetic resonance imaging and histopathological results. J Neurosurg. 2008; 108(5):909-15. DOI: 10.3171/JNS/2008/108/5/0909. View

4.
Yoshida D, Kim K, Yamazaki M, Teramoto A . Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol. 2005; 16(2):123-31. DOI: 10.1385/ep:16:2:123. View

5.
Liu Z, Chang C, Pai P, Wei K, Jung S, Chen N . Clinical features and surgical outcome of clinical and subclinical pituitary apoplexy. J Clin Neurosci. 2010; 17(6):694-9. DOI: 10.1016/j.jocn.2009.11.012. View